Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2025-12-29 @ 10:09 AM
Study NCT ID:
NCT01499667
Status:
TERMINATED
Last Update Posted:
2014-08-08
First Post:
2011-08-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-09
Start Date Type:
None
Primary Completion Date:
2012-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-11
Completion Date Type:
ACTUAL
First Submit Date:
2011-08-18
First Submit QC Date:
None
Study First Post Date:
2011-12-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2013-11-25
Results First Submit QC Date:
None
Results First Post Date:
2014-04-04
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-08-06
Last Update Post Date:
2014-08-08
Last Update Post Date Type:
ESTIMATED